Sofgen Pharma Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Melissa Angelini
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.1yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively
Mar 28
Is Procaps Group S.A. (NASDAQ:PROC) Worth US$3.7 Based On Its Intrinsic Value?
Feb 02Calculating The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)
Feb 01Procaps Group reports Q2 results
Aug 30Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)
Jan 10CEO
Melissa Angelini (43 yo)
Ms. Melissa Angelini served as Interim Co-Chief Executive Officer at Sofgen Pharma S.A. (formerly known as Procaps Group S.A.) from January 29, 2025 until July 25, 2025 and serves as its Interim Chief Exec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.1yrs | no data | 0.69% $ 1.1m | |
| Interim Chief Executive Officer | less than a year | no data | no data | |
| Interim Chief Financial Officer | 1.1yrs | no data | no data | |
| Chief Optimization and Rationalization Officer | 1.1yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: PROC.F's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.1yrs | no data | 0.69% $ 1.1m | |
| Board Observer | 2.9yrs | no data | 0% $ 0 | |
| Independent Director | 3yrs | no data | no data | |
| Director | 1.1yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: PROC.F's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/11 14:46 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sofgen Pharma S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Samuel Campos Alves | BTG Pactual |